Navigation Links
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Date:4/28/2009

ortantly, the men with advanced prostate cancer who have participated in our clinical trials over the last decade and whose courage and contribution have significantly advanced the understanding and treatment of prostate cancer and the potential role of cancer immunotherapies," added Dr. Gold.

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases and approximately 28,660 men expected to die from the disease in 2008. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

IMPACT Study Detail and Additional Results

IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) was a 512-patient, multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, androgen-independent prostate cancer, and the primary endpoint was overall survival.

In addition to the results described above, the treatment effect was consistent across multiple patient subsets and remained consistent using the log rank test and an unadjusted Cox model (HR=0.766, p-value=0.023), and after adjustment for docetaxel use following investigational therapy (HR=0.763; p-value=0.036). Prostate cancer-specific survival also favored the PROVENGE arm (HR=0.772; p-value=0.036). Consistent with other trials in this patient population, PROVENGE did not significantly delay time to progression. The adverse events seen more commonly in PROVENGE-treated patients were chills, fever, and headache. These events were primarily low grade with a short duration of 1-2 days following infusion.

About PROVENGE

PROVENGE(R) (sipuleucel-T), an investigational product in development for men with androgen-indep
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, announced today that it has entered ... of common stock and 3,605,042 unregistered warrants in ... for one registered share of common stock and ... of common stock will be $3.475.  The warrants ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
(Date:9/19/2014)... LOS ANGELES , Sept. 19, 2014  CytRx ... and development company specializing in oncology, today announced that ... will present at BioCentury,s 2014 NewsMakers in the Biotech ... p.m. Eastern Time. The conference will take place at ... City . A live and archived ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... Rochester Medical Corporation (Nasdaq: ROCM ) today announced that it is ... healthcare alliance. , , , ... with more than 800 suppliers and Rochester Medical is one of 38 ... outstanding management of Premier agreements and drive toward the mutual goal of ...
... June 22 Hospira, Inc. (NYSE: HSP ... it has received U.S. Food and Drug Administration (FDA) approval ... g vials.  The medication, a carbapenem that belongs to the ... Merrem® I.V. Sales of the name-brand product in ...
Cached Medicine Technology:Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 2Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 3Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 2Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 3
(Date:9/20/2014)... SATURDAY, Sept. 20, 2014 (HealthDay News) -- As flu ... avoid infection is to get a flu shot and ... A primary care doctor can vaccinate people against ... issues patients may have. Retail stores may provide flu ... medical advice, said Dr. Jorge Parada, medical director of ...
(Date:9/20/2014)... New PharmaPoint Drug Evaluation report, ... 2023?. The asthma market saw very slow growth ... saturated with relatively efficacious standard therapies, such as ... and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and ... the launch of seven novel targeted biologic agents ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
(Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
(Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... million of their customers may have had their credit card ... late last year, spawning a slew of headline articles ... but those weren’t the only eye opening numbers. , ... numbers were stolen, almost like it’s a way to score ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5
... in Maryland, USA, has launched a major initiative against the ... all mothers who deliver their babies at the Centre to ... ,Shaking a baby too hard could result in ... ,Nearly 70 percent of shaken baby syndrome cases ...
... prevent bites and therefore don’t prevent disease transmission, according ... be manufactured, advertised or used for mosquito bite and ... lead author A. Ali Enayati, Ph.D., lecturer in medical ... Sari, Iran. ,The review appears in the ...
... surgical robot developed by the University of Washington, leaves for ... in NASA's mission to submerge a surgeon and robotic gear ... system will be put through its paces in an underwater ... in Seattle will guide its movements. ,The 12th ...
... The World Health Organization (WHO) Thursday expressed alarm over ... motorcycles in Asia//, warning that the situation has become ... that young motorcyclists make up a significant percentage of ... countries, such as Cambodia and Malaysia. ,"Factors ...
... benefits of a key ingredient in Cannabis, which may help ... that cannabis could help fight brain, prostate and skin cancers. ... growth by 50%, during studies conducted on mice, suggesting that ... the study, the researchers observed that THC was able to ...
... health workers should focus their efforts on strengthening HIV/AIDS ... not overcome the pandemic, Kevin De Cock, director of ... deputy director of UNAIDS, said on Tuesday during a ... comments follow the release of a report on Tuesday ...
Cached Medicine News:Health News:Counseling to Mothers Against too Much Shaking of Children 2Health News:Electronic Mosquito Repellents Fail to Prevent Malaria Transmission 2Health News:Robotic Surgeon to Team Up With Doctors, Astronauts on NASA Mission 2Health News:Robotic Surgeon to Team Up With Doctors, Astronauts on NASA Mission 3Health News:U.N. Officials Call on Countries To Strengthen HIV/AIDS Prevention Efforts 2
... InstaCheck® multi-drug test device provides ... easily. Negative results can be ... 3 minutes; positive results require ... one-time urine sample application will ...
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
... QuickScreen™ At Home Drug Test is the first ... for home use. The kit includes a rapid ... read instructions, a handbook with frequently asked questions ... sample to the laboratory if the screening device ...
... popular onsite test! QuickScreen™ multi-panel dip cards ... and your choice of any conceivable combination ... total flexibility for your drug testing program. ... and the built-in timer tells you when ...
Medicine Products: